AbCellera Biologics Inc. Property, Plant and Equipment, Gross
AbCellera Biologics Inc. (ABCL) had Property, Plant and Equipment, Gross of $304.24 million as of 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2023-11-02
- 2023-09-30: Property, Plant and Equipment, Gross $304.24M.
- 2023-06-30: Property, Plant and Equipment, Gross $283.85M.
- 2023-03-31: Property, Plant and Equipment, Gross $254.52M.
- 2022-12-31: Property, Plant and Equipment, Gross $235.73M.
| Period end | Property, Plant and Equipment, Gross |
|---|---|
| 2023-09-30 | $304.24M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $283.85M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $254.52M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $235.73M 10-Q · filed 2023-11-02 |
| 2022-09-30 | $216.34M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $162.40M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $133.26M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $121.44M 10-K · filed 2023-02-21 |
| 2021-09-30 | $100.09M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $94.82M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $40.90M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $23.51M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |